Instructions for Bifidumbacterin Forte probiotic 5 doses powder
English product name
Bifidumbacterin Forte
Release form
caps. 50 million KOE (5 doses): cans of 10, 18 or 30 pcs.
caps. 50 million KOE (5 doses): fl 10, 18 or 30 pcs
d/ingestion powder 50 million SOME (5 doses): park. 10 or 30 pcs
Description Bifidumbacterin Forte:
Capsules are solid, gelatinous, body - white color, cap - blue color; The contents of the capsules are powder of light grey to dark grey colour with black coal particles and possible tints of beige colour, with a faint sour-milk smell.
1 cap. (5 doses)
Bifidobacterium bifidum at least 50 million. SOME
Auxiliary substances: lactose.
ATC codes
A07FA Biological antidiarrhoeal preparations regulating the balance of intestinal microflora
Clinical-pharmacological groups / Group affiliation
Preparation for regulating the balance of intestinal microflora (probiotic)
Active substance
Bifidobacterium bifidum
Pharmacotherapy group
MIBP eubiotic
Storage Conditions Bifidumbacterin Forte
Packages should be stored at a temperature not higher than 10°C. The lower temperature limit is not limited. The transport is carried out at a temperature not exceeding 10°C; transport at temperatures up to 20°C is allowed up to 10 days. The capsules should be stored at a temperature of 2° to 10°C.
Best before date
Shelf life is 1 year.
The drug Bifidumbacterin Forte should be stored in a place inaccessible to children.
Testimony Bifidumbacterin Forte:
- As monotherapy or as part of complex therapy:
- intestinal dysbacteriosis;
- acute intestinal infections established (shigellosis, salmonellosis, staphylococcal enterocolitis, rotavirus infection) and unspecified etiology;
- food toxicoinfections;
- ORVI;
- chronic diseases with gastrointestinal tract infection (ulcerative stomach and duodenal ulcer, pancreatitis, cholecystitis, diseases of the liver and biliary tract) accompanied by intestinal dysbacteriosis;
- chronic constipation;
- malabsorption syndrome;
- allergic diseases accompanied by intestinal dysbacteriosis;
- pneumonia, acute and chronic bronchitis, inflammatory diseases of the urogenital tract, accompanied by intestinal dysbacteriosis;
- Intestinal dysbacteriosis caused by antibiotics, antibacterial drugs, hormones, NSAIDs;
- diarrhea in patients treated for long periods with antibiotics and other antibacterial drugs Bifidumbacterin Forte;
- correction of intestinal microbiocenosis and prevention of pyo-inflammatory diseases in patients with surgical profile during preoperative preparation and after operations on intestines, liver, pancreas.
- For prevention:
- Intrahospital infections in maternity hospitals and hospitals
- Dysbacteriosis in children and adults with frequent ARVI.
Pharmacological effect:
A preparation of biological origin regulating the balance of intestinal microflora, a probiotic.
The action of the preparation is caused by a high concentration of bifidobacteria sorbed on particles of activated carbon, which are antagonists of a wide range of pathogenic (including Shigella spp., Salmonella spp., Staphylococcus aureus) and opportunistic pathogens (including Proteus spp., Klebsiella spp.).
Bifidobacteria, sorbed on a specially prepared carrier, provide increased clinical efficiency, rapid restoration of normal microflora. Microflora, being a natural biosorbent, accumulates a significant amount of toxic substances entering from outside or forming in the body and decomposes them into non-toxic components. The sorbed bifidobacteria, forming microcolonies, intensively activate the restorative and metabolic processes, wall-based digestion, synthesis of vitamins and amino acids, and immune defense of the body.
Method of use, course and dosage:
The drug Bifidumbacterin Forte is taken inside during meals, if necessary - regardless of the meal.
The preparation in the form of capsules is prescribed to adults and children aged 3 and older. The capsules are taken with boiled water or an acidic milk product. For children, when necessary, the capsules are opened and the contents are mixed with liquid food, preferably with an acidic milk product. The capsule contents can be mixed with 20-50 ml boiling water at room temperature, thus a muddy suspension with particles of sorbent in black is formed. The resulting water mixture should be drunk, not achieving complete dissolution.
The preparation in the form of a powder for oral administration is prescribed to adults and children of all age groups. The powder is mixed with liquid food, preferably with an acidic milk product, and for newborns and babies with mother milk or an artificial feeding mixture before use.
Contraindications for use:
individual drug Bifidumbacterin Forte intolerance.
Special Instructions
With care, the drug should be used for lactase insufficiency.
Terms of Sale
The drug is allowed to be used as a non-prescription drug.
Use in children
The drug Bifidumbacterin Forte is used in children (see Dosage mode).
- Nosology (ICD codes)
- A02
- Other salmonella infections
- A03
- Shigellosis
- A05.0
- Staphylococcal food poisoning
- A05.9
- Bacterial food poisoning unspecified
- A08
- Viral and other refined intestinal infections
- A08.0
- Rotavirus enteritis
- A09
- Other gastroenteritis and colitis of infectious and unspecified origin
- J06.9
- Acute upper respiratory tract infection unspecified
- J15
- Bacterial pneumonia not classified elsewhere
- J20
- Acute bronchitis
- J42
- Chronic bronchitis unspecified
- K25
- Stomach ulcer
- K26
- Duodenum ulcer
- K59.0
- Constipation
- K63.8
- Other refined bowel diseases
- K73
- Chronic hepatitis not classified elsewhere
- K81.1
- Chronic cholecystitis
- K83.0
- Holangit
- K86.1
- Other chronic pancreatitis
- K90
- Intestinal absorption disorders
- N10
- Acute tubuloinsterstitial nephritis (acute pielonephritis)
- N11
- Chronic tubulointerstitial nephritis (chronic pyelonephritis)
- N30
- Cystitis
- N34
- Urethritis and urethral syndrome
- Y40
- Systemic antibiotics
- Y42
- Hormones and their synthetic substitutes and antagonists not classified in other rubrics
- Y45
- Analgesic, antipyretic and anti-inflammatory agents
- Z51.4
- Preparatory procedures for follow-up treatment or examination not classified elsewhere
